Adenosine Signaling in Sickle Cell Disease
Understanding a disease’s mechanistic pathway is central for novel treatment development. Metabolon’s technology is uniquely positioned to accelerate MOA, identify biomarkers, further personalized medicine and tailor therapy approaches.
Sickle cell disease (SCD) is an inheritable hemolytic disorder caused by a single point mutation. Despite knowledge of the molecular defect associated with SCD, mechanism-specific treatment options are lacking.